BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Merry Life Biomedical Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Merry Life Biomedical Co.\, Ltd.'
 s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07612150-783@assetmemo.bio
DTSTAMP:20261121T005948Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:TML-6: Phase 2 readout est. (NCT07612150)
DESCRIPTION:TML-6\, phase 2\, Alzheimer's Disease.\nStudy: A Study to Evalu
 ate the Safety\, Tolerability\, and Efficacy of TML-6 in Participants With
  Early Alzheimer's Disease\nEstimated primary completion: 30 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tml-6#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07612150
URL:https://assetmemo.bio/drug/tml-6#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
